 |
 |
|
|
RESÚMENES OCTUBRE 2006 |
Psychotic Disorders
& Antipsychotics
(Haga un click en la información del journal para acceder al resúmen)
Early changes of plasma
lipids during treatment with atypical antipsychotics
Rettenbacher,
Maria A; Ebenbichler, Christoph;
Hofer, Alex; Kemmler, George; Baumgartner, Susanne; Edlinger, Monika; Hummer, Martina; Lechleitner,
Monika; Wolfgang Fleischhacker, W
International
Clinical Psychopharmacology. 21(6):369-372, November 2006
Persistence with polypharmacy and excessive dosing in patients with
schizophrenia treated in four European countries
Barbui,
Corrado; Nose, Michela; Mazzi, Maria Angela; Thornicroft,
Graham; Schene, Aart;
Becker, Thomas; Bindman, Jonathan; Leese, Morven; Helm, Hedda; Koeter, Maarten; Weinmann, Stefan; Tansella,
Michele
International
Clinical Psychopharmacology. 21(6):355-362, November 2006
Hyperlipidemia
Following Treatment With Antipsychotic Medications
Mark Olfson, Steven C. Marcus, Patricia
Corey-Lisle, A.V. Tuomari, Patricia Hines, and
Gilbert J. L’Italien
American
Journal of Psychiatry 163:1821-1825, October 2006
Brain volume
changes in the first year of illness and 5-year outcome of schizophrenia
W. CAHN, N. E. M. van HAREN, H. E. HULSHOFF POL, H. G. SCHNACK, E.
CASPERS, D. A. J. LAPONDER, and R. S. KAHN
The British Journal of Psychiatry (2006) 189:
381-382
Randomized Controlled Trial of the Effect on Quality
of Life of Second- vs First-Generation Antipsychotic
Drugs in Schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in
Schizophrenia Study (CUtLASS 1)
Peter B. Jones, Thomas R. E. Barnes, Linda Davies,
Graham Dunn, Helen Lloyd, Karen P. Hayhurst, Robin M.
Murray, Alison Markwick, Shôn
W. Lewis
Arch Gen Psychiatry. 2006;63:1079-1087
Neurobiology of
Schizophrenia
Christopher A. Ross, Russell L. Margolis,
Sarah A.J. Reading, Mikhail Pletnikov and Joseph T.
Coyle
Neuron. Volume 52, Issue 1, 5
October 2006, Pages 139-153
Prejudice and schizophrenia: a review of the 'mental illness is an
illness like any other' approach
J. Read, N. Haslam, L. Sayce,
E. Davies
Acta Psychiatrica Scandinavica. Volume 114 Page 303 - November 2006
The treatment of negative symptoms and deficit states of chronic
schizophrenia: olanzapine compared to amisulpride and
placebo in a 6-month double-blind controlled clinical trial
Y. Lecrubier, P. Quintin,
M. Bouhassira, E. Perrin, S. Lancrenon
Acta Psychiatrica Scandinavica. Volume 114 Page 319 - November 2006
Two years of continued early treatment for recent-onset schizophrenia: a
randomised controlled study
R. W. Grawe, I. R. H. Falloon, J. H. Widen, E.
Skogvoll
Acta Psychiatrica Scandinavica. Volume 114 Page 328 - November 2006
Treated incidence of first-episode psychosis in the catchment
area of EPPIC between 1997 and 2000
G. P. Amminger, M. G.
Harris, P. Conus, M. Lambert, K. S. Elkins, H.-P. Yuen, P. D. McGorry
Acta Psychiatrica Scandinavica. Volume 114 Page 337 - November 2006
MRI volumetric and 31P MRS metabolic correlates of caudate
nucleus in antipsychotic-naïve schizophrenia
P. N. Jayakumar, G. Venkatasubramanian, M. S.
Keshavan, J. S. Srinivas, B. N. Gangadhar
Acta Psychiatrica
Scandinavica. Volume 114 Page 346 - November 2006
Cerebellar and other neurological soft signs in antipsychotic-naïve
schizophrenia
S. Varambally, G. Venkatasubramanian, J.
Thirthalli, N. Janakiramaiah, B. N. Gangadhar
Acta Psychiatrica
Scandinavica. Volume 114 Page
352 - November 2006
Cognitive
Dysfunction in Schizophrenia. Convergence of Gamma-Aminobutyric
Acid and Glutamate Alterations
David A. Lewis, Bita Moghaddam
Arch Neurol. 2006;63:1372-1376
Diagnosing
Psychotic Disorders in the Emergency Department in the Context of Substance Use
Bella M. Schanzer, Michael B. First, Boanerges Dominguez, Deborah S. Hasin,
and Carol L. M. Caton
Psychiatr Serv
57:1468-1473, October 2006
Predicting Medication-Free Treatment Response in Acute
Psychosis: Cross-Validation From the Finnish
Need-Adapted Project
Bola,
John Robert; Lehtinen, Klaus; Aaltonen, Jukka; Rakkolainen, Viljo; Syvalahti,
Erkka; Lehtinen, Ville
Journal
of Nervous & Mental Disease. 194(10):732-739, October 2006
Adherence to Medication and Quality of Life in People With Schizophrenia: Results of a
Puschner, Bernd; Born, Anja; Giebler, Anne; Helm, Hedda; Leese, Morven;
Bindman, Jonathan P; Gray, Richard J; Schene, Aart; Kikkert,
Martijn; Burti, Lorenzo; Marrella, Giovanna; Becker, Thomas
Journal of Nervous & Mental Disease.
194(10):746-752, October 2006
What is the value of
treating schizophrenia?
Australian and New Zealand Journal of Psychiatry. Volume 40 Page 963 -
November/December 2006
Antipsychotic medication
dispensing and associated odds ratios of death in elderly veterans and war
widows, 2001
Jean
Hollis , Stephen Touyz ,
David Grayson , Loelle Forrester
Australian and New Zealand Journal of Psychiatry. Volume 40 Page 981 - November/December
2006
Four symptom dimensions in
outpatients with schizophrenia
Victòria Villalta-Gil, Miriam Vilaplana,
Susana Ochoa, Montserrat Dolz, Judith Usall, Josep Maria Haro,
José Almenara, Juan Luis González,
Carolina Lagares
Compr Psychiatry. Volume 47, Issue 5,
Pages 384-388 (September 2006)
Reduction in
psychotic symptoms as a predictor of patient satisfaction with antipsychotic
medication in schizophrenia: Data from a randomized double-blind trial
Georges M Gharabawi, Andrew Greenspan, Marcia
FT Rupnow, Colette Kosik-Gonzalez,
Cynthia A Bossie, Young Zhu, Amir
H Kalali and A George Awad
BMC Psychiatry 2006, 6:45
A Practical
Clinical Trial Comparing Haloperidol, Risperidone,
and Olanzapine for the Acute Treatment of First-Episode Nonaffective
Psychosis
Benedicto Crespo-Facorro,
Rocío Pérez-Iglesias, MariLuz Ramirez-Bonilla, Obdulia Martínez-García, Javier LLorca,
and José Luis Vázquez-Barquero
J Clin Psychiatry 2006;67:1511-1521
Switching to
Olanzapine After Unsuccessful Treatment With Risperidone During the First Episode of Schizophrenia: An
Open-Label Trial
Hitoshi Takahashi, Mitsuhiro Kamata, Keizo Yoshida, Jun Ishigooka, and Hisashi Higuchi
J Clin Psychiatry 2006;67:1577-1582
Antipsychotic
Adherence Over Time Among Patients Receiving Treatment
for Schizophrenia: A Retrospective Review
Marcia Valenstein,
Dara Ganoczy, John F.
McCarthy, Hyungjin
J Clin Psychiatry 2006;67:1542-1550
Improvement of
patient compliance after switching from conventional neuroleptics
to the atypical neuroleptic amisulpride
Michael Linden, Tabea Scheel, Franz-Xaver
Eich
Journal
of Psychopharmacology, Vol. 20, No. 6, 815-823 (2006)
Formation of
immature neutrophil leucocytes in schizophrenic
patients treated with various antipsychotic drugs: comparisons and predictions
J. M. Delieu, R. W. Horobin,
J. K. Duguid
Journal
of Psychopharmacology, Vol. 20, No. 6, 824-828 (2006)
The influence of
the CYP2D6 polymorphism on psychopathological and extrapyramidal
symptoms in the patients on long-term antipsychotic treatment
Blanka Kores Plesnic
ar,
Bojan Zalar, Katja Breskvar, Vita Dolz
an
Journal of Psychopharmacology, Vol. 20, No. 6,
829-833 (2006)
Gender, age,
ethnicity and area of residence influence incidence of psychotic disorders
Kirkbride JB,
Fearon P, Morgan C, et al.
Evidence-Based Mental
Health 2006;9:107
The effectiveness and predictors of response
to antipsychotic agents to treat impaired quality of life in schizophrenia: A
12-month naturalistic follow-up study with implications for confounding
factors, antidepressants, anxiolytics, and mood
stabilizers
Michael S. Ritsner and Anatoly Gibe
Gender differences in prolactin
elevation induced by olanzapine in Japanese drug-naïve schizophrenic patients
Kazushi Sawamura, Yutaro Suzuki, Naoki
Fukui, Takuro Sugai and
Toshiyuki Someya
Improvement in social functioning in
outpatients with schizophrenia with prominent negative symptoms treated with
olanzapine or risperidone in a 1 year
randomized, open-label trial
Antonio Ciudad,
José M. Olivares, Manuel Bousoño, Juan C. Gómez and Enrique Álvarez